Oral COVID-19 antiviral prescribing in Australian general practice – a retrospective observational study
Judith Thomas A * , Abbish Kamalakkannan A , Mirela Prgomet A , Karina Gardner B , Precious McGuire C , Geoffrey Campbell D Andrew Georgiou AA
B
C
D
Abstract
This study aimed to gain a comprehensive understanding of oral COVID-19 antiviral prescribing in Australian general practice.
The study was a retrospective observational cohort study. Routinely collected, de-identified, Australian general practice consultation and prescription data was used with permission from participating primary health networks, from 938 general practices between March 2022 and September 2023. Study cohorts were patients aged ≥15 encompassing (i) an ‘antiviral cohort’ comprising patient records with ≥1 oral COVID-19 antiviral prescription/s and (ii) a ‘comparison cohort’ of remaining records. Primary outcome measures were the frequency and type of oral COVID-19 antivirals prescribed, and sociodemographic and health characteristics of patients prescribed antivirals. Secondary measures were the frequency of antiviral repeat prescribing and consultation modality.
Within the study population of 3,813,051 patients, oral COVID-19 antivirals were prescribed to 3.39% (129,267) of patients including 14.79% (82,215/555,757) of patients aged ≥70 years. Molnupiravir prescribing exceeded nirmatrelvir–ritonavir across all study months. Proportionally, antiviral prescribing was higher in the female population (74,709/2,059,676: 3.63%), Victoria (81,184/2,222,837: 3.65%), residing in high socioeconomic advantage areas (87,530/2,224,501: 3.93%), and ages 80–84 years (16,419/100,911: 16.27%). Of patients prescribed COVID-19 antivirals, 7.27% (9402/129,267) had repeat prescribing. Cardiovascular and musculoskeletal conditions were the most prevalent chronic diagnoses, and telehealth (58,660/107,727: 54.45%) exceeded face-to-face consultations.
Oral COVID-19 antiviral prescribing volumes in general practice may serve as an indicator of periods of increased transmission of COVID-19, through increases in prescribing activity. Telehealth exceeding face-to-face for oral COVID-19 antiviral prescribing supports continued access to telehealth to reduce exposure to COVID-19 and provide time-critical access to treatment.
Keywords: antiviral, Australia, COVID-19, general practice, molnupiravir, nirmatrelvir–ritonavir, prescribing, SARS-CoV-2, telehealth.
References
Al Naji H, Inglis JM, Tucker E, Rowett D, Larcombe R, Medlin S, Mangoni AA, Thynne T (2024) Prescribing of antivirals for COVID-19 in a South Australian local health network according to statewide guidelines. Internal Medicine Journal 54(1), 183-186.
| Crossref | Google Scholar |
Allard NL, Canevari J, Haslett N, Cowie BC (2023) Access to oral COVID-19 antivirals in the community: are eligibility criteria and systems ensuring equity? Medical Journal of Australia 218(10), 438-441.
| Crossref | Google Scholar | PubMed |
Andrews HS, Herman JD, Gandhi RT (2024) Treatments for COVID-19. Annual Review of Medicine 75, 145-157.
| Crossref | Google Scholar | PubMed |
Australian Bureau of Statistics (2021a) Search census data. Available at https://abs.gov.au/census/find-census-data/search-by-area
Australian Bureau of Statistics (2021b) Socio-Economic Indexes for Areas (SEIFA), Australia. Available at https://www.abs.gov.au/statistics/people/people-and-communities/socio-economic-indexes-areas-seifa-australia/latest-release
Australian Government Department of Health and Aged Care (2022a) Factsheet – Covid 19 treatment – Lagevrio® (molnupiravir) PBS listing (updated 6 March 2024). Available at https://www.pbs.gov.au/publication/factsheets/covid-19-treatments/PBS-Factsheet-lagevrio-molnupiravir-March-2024.pdf
Australian Government Department of Health and Aged Care (2022b) Factsheet – Covid 19 treatment – Paxlovid® (nirmatrelvir and ritonavir) PBS listing (updated 6 March 2024). Available at https://www.pbs.gov.au/publication/factsheets/covid-19-treatments/PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-March-2024.pdf
Australian Government Department of Health and Aged Care (2023) COVID-19 Oral Treatments – Factsheet. Available at https://www.health.gov.au/sites/default/files/2023-01/covid-19-oral-treatments-fact-sheet.pdf
Australian Government Department of Health and Aged Care (2024) COVID-19 reporting: COVID-19 treatments. Available at https://www.health.gov.au/topics/covid-19/reporting#covid19-treatments
Australian Government Department of Health and Aged Care – MBS Online (2022) Assessment for a COVID-19 oral anti-viral medication. Available at https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Factsheet-Anti-Virals-C19
Australian Government – Services Australia (2024) Pharmaceutical benefits schedule item reports. Available at http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp
Clarke N, O’Keeffe J, Yerramilli A, Bartolo C, Mothobi N, Muleme M, McNamara B, O’Brien D, Athan E, Hussain MA (2024) Use of targeted SMS messaging to encourage COVID-19 oral antiviral uptake in South West Victoria. Public Health Research & Practice 34, e33342309.
| Crossref | Google Scholar |
COVID-19 Epidemiology and Surveillance Team (2023) COVID-19 Australia: epidemiology report 79: reporting period ending 24 September 2023. Communicable Diseases Intelligence 47, 1-22.
| Crossref | Google Scholar |
Imai C, Amin J, Prgomet M, Pearce C, Georgiou A (2022) An increase in antibiotic prescribing for respiratory tract infections through telehealth consultations: retrospective study in Australian general practice. Journal of Medical Internet Research 24(10), e40876.
| Crossref | Google Scholar |
Kaul CM, Cohen GM, Silverstein M, Wallach AB, Diago-Navarro E, Holzman RS, Foote MK (2023) Understanding the relationship between antiviral prescription data and COVID-19 Incidence in New York City: a retrospective cohort study. Open Forum Infectious Diseases 10(6), ofad281.
| Crossref | Google Scholar |
Lopez D, Pritchard D, Sanfilippo FM, Kelty E, Page A, Etherton-Beer C, Almeida OP, Preen DB (2024) Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: a retrospective observational study. Infectious Diseases Now 54(6), 104953.
| Crossref | Google Scholar |
NSW Health (2022) Remember lessons learned as COVID-19 isolation ends. Available at https://www.health.nsw.gov.au/news/Pages/20221012_00.aspx
Paraskevis D, Gkova M, Mellou K, Gerolymatos G, Psalida N, Gkolfinopoulou K, Kostaki E-G, Loukides S, Kotanidou A, Skoutelis A, Thiraios E, Saroglou G, Zografopoulos D, Filippou D, Mossialos E, Zaoutis T, Gaga M, Tsiodras S, Antoniadou A (2023) Real-world effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as treatments for COVID-19 in patients at high risk. The Journal of Infectious Diseases 228(12), 1667-1674.
| Crossref | Google Scholar | PubMed |
Pearce C, McLeod A, Rinehart N, Ferrigi J, Shearer M (2019) What a comprehensive, integrated data strategy looks like: the Population Level Analysis and Reporting (POLAR) program. Studies in Health Technology and Informatics 264, 303-307.
| Crossref | Google Scholar | PubMed |
Sheppeard A (2022) Private antivirals for covid: what GPs need to know. The Medical Republic. Available at https://www.medicalrepublic.com.au/private-antivirals-for-covid-what-gps-need-to-know/7897
Snoswell CL, Caffery LJ, Taylor ML, Mendis R, Haydon HM, Thomas E, Smith AC, Centre for Online Health The University of Queensland (2024) Telehealth and coronavirus: Medicare Benefits Schedule (MBS) activity in Australia. Available at https://coh.centre.uq.edu.au/telehealth-and-coronavirus-medicare-benefits-schedule-mbs-activity-australia
The Hon Daniel Andrews MP Premier (2022) Media release – changes to pandemic management. Available at https://www.premier.vic.gov.au/sites/default/files/2022-10/221007%20-%20Changes%20To%20Pandemic%20Management.pdf
Van Heer C, Majumdar SS, Parta I, Martinie M, Dawson R, West D, Hewett L, Lister D, Sutton B, O’Brien DP, Cowie BC (2023) Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study. The Lancet Regional Health–Western Pacific 41, 100917.
| Crossref | Google Scholar |
Wabe N, Thomas J, Sezgin G, Sheikh MK, Gault E, Georgiou A (2022) Medication prescribing in face-to-face versus telehealth consultations during the COVID-19 pandemic in Australian general practice: a retrospective observational study. BJGP Open 6(1), BJGPO.2021.0132.
| Crossref | Google Scholar |
World Health Organization (2023) Therapeutics and COVID-19: living guideline, 10 November 2023. Available at https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.2
